202 related articles for article (PubMed ID: 35832924)
1. Item-Level Story Recall Predictors of Amyloid-Beta in Late Middle-Aged Adults at Increased Risk for Alzheimer's Disease.
Mueller KD; Du L; Bruno D; Betthauser T; Christian B; Johnson S; Hermann B; Koscik RL
Front Psychol; 2022; 13():908651. PubMed ID: 35832924
[TBL] [Abstract][Full Text] [Related]
2. Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease.
Mueller KD; Koscik RL; Du L; Bruno D; Jonaitis EM; Koscik AZ; Christian BT; Betthauser TJ; Chin NA; Hermann BP; Johnson SC
Cortex; 2020 Oct; 131():137-150. PubMed ID: 32861209
[TBL] [Abstract][Full Text] [Related]
3. Associations between recall of proper names in story recall and CSF amyloid and tau in adults without cognitive impairment.
Hale MR; Langhough R; Du L; Hermann BP; Van Hulle CA; Carboni M; Kollmorgen G; Basche KE; Bruno D; Sanson-Miles L; Jonaitis EM; Chin NA; Okonkwo OC; Bendlin BB; Carlsson CM; Zetterberg H; Blennow K; Betthauser TJ; Johnson SC; Mueller KD
Neurobiol Aging; 2024 Jan; 133():87-98. PubMed ID: 37925995
[TBL] [Abstract][Full Text] [Related]
4. Serial position effects in the Logical Memory Test: Loss of primacy predicts amyloid positivity.
Bruno D; Mueller KD; Betthauser T; Chin N; Engelman CD; Christian B; Koscik RL; Johnson SC
J Neuropsychol; 2021 Sep; 15(3):448-461. PubMed ID: 33274833
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Remote and Fully Automated Story Recall Task to Assess for Early Cognitive Impairment in Older Adults: Longitudinal Case-Control Observational Study.
Skirrow C; Meszaros M; Meepegama U; Lenain R; Papp KV; Weston J; Fristed E
JMIR Aging; 2022 Sep; 5(3):e37090. PubMed ID: 36178715
[TBL] [Abstract][Full Text] [Related]
6. The recency ratio assessed by story recall is associated with cerebrospinal fluid levels of neurodegeneration biomarkers.
Bruno D; Jauregi Zinkunegi A; Kollmorgen G; Suridjan I; Wild N; Carlsson C; Bendlin B; Okonkwo O; Chin N; Hermann BP; Asthana S; Zetterberg H; Blennow K; Langhough R; Johnson SC; Mueller KD
Cortex; 2023 Feb; 159():167-174. PubMed ID: 36630749
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
8. Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation.
Racine AM; Adluru N; Alexander AL; Christian BT; Okonkwo OC; Oh J; Cleary CA; Birdsill A; Hillmer AT; Murali D; Barnhart TE; Gallagher CL; Carlsson CM; Rowley HA; Dowling NM; Asthana S; Sager MA; Bendlin BB; Johnson SC
Neuroimage Clin; 2014; 4():604-14. PubMed ID: 24936411
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
10. Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study.
Clark LR; Racine AM; Koscik RL; Okonkwo OC; Engelman CD; Carlsson CM; Asthana S; Bendlin BB; Chappell R; Nicholas CR; Rowley HA; Oh JM; Hermann BP; Sager MA; Christian BT; Johnson SC
Alzheimers Dement; 2016 Jul; 12(7):805-14. PubMed ID: 26806386
[TBL] [Abstract][Full Text] [Related]
11. A comparison of diagnostic performance of word-list and story recall tests for biomarker-determined Alzheimer's disease.
Bruno D; Jauregi Zinkunegi A; Kollmorgen G; Carboni M; Wild N; Carlsson C; Bendlin B; Okonkwo O; Chin N; Hermann BP; Asthana S; Blennow K; Langhough R; Johnson SC; Pomara N; Zetterberg H; Mueller KD
J Clin Exp Neuropsychol; 2023 Oct; 45(8):763-769. PubMed ID: 37571873
[TBL] [Abstract][Full Text] [Related]
12. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
[TBL] [Abstract][Full Text] [Related]
13. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
14. Primacy and recency effects in verbal memory are differentially associated with post-mortem frontal cortex p-tau 217 and 202 levels in a mixed sample of community-dwelling older adults.
Gicas KM; Honer WG; Petyuk VA; Wilson RS; Boyle PA; Leurgans SE; Schneider JA; De Jager PL; Bennett DA
J Clin Exp Neuropsychol; 2023 Oct; 45(8):770-785. PubMed ID: 37440260
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
16. Is tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity.
Weigand AJ; Bangen KJ; Thomas KR; Delano-Wood L; Gilbert PE; Brickman AM; Bondi MW;
Brain Commun; 2020; 2(1):fcz046. PubMed ID: 32051933
[TBL] [Abstract][Full Text] [Related]
17. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
